Logo 1200x628.jpg
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
November 11, 2024 07:30 ET | CytoSorbents; Converge Biotech
CytoSorbents and Converge Biotech Partner In India to Expand CytoSorb Blood Purification Availability to Treat Sepsis and Other Deadly Conditions
Figure 1: Nasal anti-CD3 with Low and High Dose semaglutide promote Liver Homeostasis in DIO
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
October 30, 2024 08:30 ET | Tiziana Life Sciences Ltd.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Global Liver Institute Welcomes Larry R. Holden as CEO
Global Liver Institute Welcomes Larry R. Holden as CEO
September 03, 2024 09:54 ET | Global Liver Institute
Washington, DC, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Global Liver Institute (GLI), the premier liver patient advocacy organization, has appointed Larry R. Holden as the...
Renown Health pionee
Renown Health pioneers HistoSonics Edison system delivering histotripsy for non-invasive liver tumor treatment
August 08, 2024 16:18 ET | Renown Health
Reno, NEV., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Renown Health announced today that the first patients have received targeted liver tumor treatments through the Edison® System histotripsy technology,...
Logo 1200x628.jpg
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
July 30, 2024 02:00 ET | CytoSorbents
CytoSorbents new modern website launch unifies corporate and product websites and highlights "Working to Save Lives Together"
Logo 1200x628.jpg
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
July 29, 2024 08:00 ET | CytoSorbents
CytoSorbents new modern website launch unifies corporate and product websites and highlights "Working to Save Lives Together"
barinthuslogo.jpg
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 06, 2024 11:15 ET | Barinthus Biotherapeutics
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.
Organovo Logo (2 Color Med-Res-082117).png
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
April 15, 2024 08:05 ET | Organovo, Inc.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Conte
Rezdiffra
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
April 09, 2024 08:00 ET | Madrigal Pharmaceuticals, Inc.
Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) First patients have received Rezdiffra via Madrigal’s specialty pharmacy network ...
cmi_logo.png
[Latest] Global Liver Cancer Market Size/Share Worth USD 16.3 Billion by 2033 at a 14.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 03, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, April 03, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Liver Cancer Market Size, Trends and Insights By Type (Hepatocellular Carcinoma...